Group 1 - Guangshentang's stock price increased by 7.52% to 131.76 CNY per share, with a trading volume of 1.293 billion CNY and a turnover rate of 7.58%, resulting in a total market capitalization of 20.985 billion CNY [1] - Guangshentang Pharmaceutical Co., Ltd. specializes in the research, production, and sales of nucleoside antiviral drugs for hepatitis B, with 98.54% of its revenue coming from liver and gallbladder disease medications [1] - The company was established on June 28, 2001, and went public on April 22, 2015 [1] Group 2 - Among Guangshentang's top ten circulating shareholders, a fund under China Europe Fund reduced its holdings by 1.1365 million shares, now holding 708,100 shares, which represents 0.52% of the circulating shares [2] - The China Europe Medical Health Mixed A Fund (003095) has a total scale of 13.843 billion CNY and has achieved a year-to-date return of 1.4% [2] - The fund's one-year return is 16.05%, ranking 5591 out of 8127 in its category [2] Group 3 - The fund manager of China Europe Medical Health Mixed A is Ge Lan, who has a tenure of 11 years and 16 days, with a total asset scale of 35.389 billion CNY and a best fund return of 96.69% during her tenure [3] - Zhao Lei, the other fund manager, has a tenure of 222 days, managing assets of 26.943 billion CNY, with a best fund return of 2.29% during his tenure [3]